| For: | Ye CP, Qiu CZ, Huang ZX, Su QC, Zhuang W, Wu RL, Li XF. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol 2007; 13(46): 6264-6268 [PMID: 18069771 DOI: 10.3748/wjg.v13.i46.6264] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i46/6264.htm |
| Number | Citing Articles |
| 1 |
Felix H. Shek, Tracy C. W. Lai, Sarwat Fatima, Nikki P. Lee. New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. 2013; doi: 10.1007/978-1-62703-456-2_4
|
| 2 |
Jin Long Liu, Xue Jun Zhang, Zhao Zhang, An Hong Zhang, Wei Wang, Jia Hong Dong, Lian-Yue Yang. Meta-Analysis: Prognostic Value of Survivin in Patients with Hepatocellular Carcinoma. PLoS ONE 2013; 8(12) doi: 10.1371/journal.pone.0083350
|
| 3 |
Rebecca Liu, Duane A. Mitchell. Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. Cancer Immunology, Immunotherapy 2010; 59(2) doi: 10.1007/s00262-009-0757-9
|
| 4 |
J. González-Gallego, M.J. Tuñón. Apoptosis: Involvement of Oxidative Stress and Intracellular Ca2+ Homeostasi. 2009; doi: 10.1007/978-1-4020-9873-4_4
|
| 5 |
Süleyman Bayram, Hikmet Akkız, Aynur Bekar, Ersin Akgöllü. The association between the survivin −31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiology 2011; 35(6) doi: 10.1016/j.canep.2011.01.004
|
| 6 |
Tetsuhiro Tsuruma, Hidekaz Kameshima, Yuji Iwayama, Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Sato, Koichi Hirata. Apoptosome. 2010; doi: 10.1007/978-90-481-3415-1_16
|
| 7 |
Po-Yuan Ke, Steve S.-L. Chen. Hepatitis C Virus and Cellular Stress Response: Implications to Molecular Pathogenesis of Liver Diseases. Viruses 2012; 4(10) doi: 10.3390/v4102251
|
| 8 |
Giulia Fianco, Claudia Contadini, Alessandra Ferri, Claudia Cirotti, Venturina Stagni, Daniela Barilà. Caspase-8: A Novel Target to Overcome Resistance to Chemotherapy in Glioblastoma. International Journal of Molecular Sciences 2018; 19(12) doi: 10.3390/ijms19123798
|
| 9 |
N Charette, C De Saeger, Y Horsmans, I Leclercq, P Stärkel. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death & Disease 2013; 4(1) doi: 10.1038/cddis.2012.200
|
| 10 |
Seong Hwi Hong, Young Ju Lee, Eun Bi Jang, Hyun Ji Hwang, Eun Song Kim, Da Hyeon Son, Sung Yul Park, Hong Sang Moon, Young Eun Yoon. Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC. International Journal of Molecular Sciences 2023; 25(1) doi: 10.3390/ijms25010216
|
| 11 |
Nermin M. Mohamed, Rania Hassan Mohamed, John F. Kennedy, Mahmoud M. Elhefnawi, Nadia M. Hamdy. A comprehensive review and in silico analysis of the role of survivin (BIRC5) in hepatocellular carcinoma hallmarks: A step toward precision. International Journal of Biological Macromolecules 2025; 311 doi: 10.1016/j.ijbiomac.2025.143616
|
| 12 |
Mahsa Mobahat, Aru Narendran, Karl Riabowol. Survivin as a Preferential Target for Cancer Therapy. International Journal of Molecular Sciences 2014; 15(2) doi: 10.3390/ijms15022494
|
| 13 |
Isabel Fabregat. Dysregulation of apoptosis in hepatocellular carcinoma cells. World Journal of Gastroenterology 2009; 15(5): 513-520 doi: 10.3748/wjg.15.513
|
| 14 |
Venturina Stagni, Simonetta Santini, Daniela Barilà. A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase. Cancers 2012; 4(2) doi: 10.3390/cancers4020354
|